Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "Rheumatoid Arthritis (RA)"

Patients with RA Who Respond to Treatment Experience Increased Cholesterol

Lara C. Pullen, PhD  |  June 6, 2016

New research confirms that patients with rheumatoid arthritis who respond to treatment experience an increase in cholesterol levels, including total cholesterol, LDL-C and HDL-C levels. However, the use of triple therapy may be important for understanding this association and mitigating its risk…

Baricitinib Has Promising Clinical Trial Results for Treating RA

Michele B. Kaufman, PharmD, BCGP  |  May 18, 2016

Recent clinical trials have shown that baricitinib is safe and effective for treating patients with rheumatoid arthritis who have proved non-responsive to multiple biologic treatments…

Triple Therapy with Methotrexate Effective, Cheaper in RA

Larry Hand  |  April 27, 2016

NEW YORK (Reuters Health)—The combination of methotrexate, sulphasalazine and hydroxychloroquine is similar in effect as methotrexate plus biologic therapy for patients with rheumatoid arthritis (RA), according to a new network meta-analysis. “Thus, for most patients, this low-cost combination of medications should probably be tried before moving onto biologic therapy, either as initial treatment or as…

Etanercept Submitted to FDA for Approval to Treat Pediatric Plaque Psoriasis; Boehringer Ingelheim & AbbVie to Collaborate; Low Doses of Gerilimzumab Promising for RA

Michele B. Kaufman, PharmD, BCGP  |  April 13, 2016

The FDA has received an application to expand the use of etanercept to treat plaque psoriasis in pediatric patients. Boehringer Ingelheim and AbbVie have announced a collaborative partnership to develop treatments for multiple autoimmune diseases. And gerilimzumab may prove safe and effective for treating inflammatory diseases at very low doses…

Under Patient Control: Is Diet a Risk Factor for RA?

Richard Quinn  |  April 1, 2016

Two recent studies have linked diet to an increased risk for developing rheumatoid arthritis. According to one expert, this information could prove to be pivotal knowledge for individuals already at a greater risk of developing the disease…

From the Expert: Patient Access Is Key for Biosimilars in Development to Be Effective

Richard Quinn  |  March 25, 2016

Recent research by Michael Weinblatt, MD, and colleagues has demonstrated that a biosimilar derived from adalimumab is both effective and safe for treating patients with rheumatoid arthritis. But Dr. Weinblatt says, the benefits of such biosimilars hinge on cost and patient access…

Does PTSD Increase Risk of RA for Women?

Arthritis Care & Research  |  March 1, 2016

Multiple studies have linked post-traumatic stress disorder (PTSD) to an increased risk of rheumatoid arthritis (RA), specifically in men. Using data from a 22-year cohort study, researchers were able to analyze the association between PTSD and the risk of RA in women. This large study builds on and expands previous findings by exploring whether the effects of PTSD differ for RA subtypes. As a secondary objective, researchers also examined smoking as a behavioral confounder and/or mediator in the relationship between PTSD and risk for RA…

Tofacitinib Decreases Inflammation in Early RA

Michele B. Kaufman, PharmD, BCGP  |  February 12, 2016

A recent study used MRI to show that tofacitinib reduces inflammation and inhibition of the progression of structural damage in adults with early RA…

Textile Workers at Higher Risk for Rheumatoid Arthritis

Lisa Rapaport  |  February 12, 2016

(Reuters Health)—Breathing textile dust on the job is linked to an almost tripled risk of developing rheumatoid arthritis (RA), a Malaysian study suggests. While smoking is a known risk factor for RA, the findings add to evidence suggesting that environmental factors could trigger RA in some people, the researchers note in their report in Annals…

FDA Advisory Panel Strongly Backs Biosimilar Form of Remicade

Reuters Staff  |  February 6, 2016

(Reuters)—A medical advisory panel to the U.S. Food and Drug Administration on Tuesday recommended approval of a cheaper biosimilar form of Johnson & Johnson’s arthritis drug Remicade (infliximab) that could eventually batter sales of the branded product. The panel, by a vote of 21-3, supported use of the biosimilar from Celltrion Inc. and Pfizer Inc.,…

  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • 30
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences